KPC Pharmaceuticals Inc banner

KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 9.5 CNY Market Closed
Market Cap: ¥7.2B

P/S

1.1
Current
28%
Cheaper
vs 3-y average of 1.5

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
1.1
=
Market Cap
¥8.5B
/
Revenue
¥6.6B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
1.1
=
Market Cap
¥8.5B
/
Revenue
¥6.6B

Valuation Scenarios

KPC Pharmaceuticals Inc is trading below its 3-year average

If P/S returns to its 3-Year Average (1.5), the stock would be worth ¥13.14 (38% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+260%
Average Upside
120%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 1.1 ¥9.5
0%
3-Year Average 1.5 ¥13.14
+38%
5-Year Average 1.4 ¥12.36
+30%
Industry Average 3.9 ¥34.16
+260%
Country Average 2.8 ¥24
+153%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥8.5B
/
Jan 2026
¥6.6B
=
1.1
Current
¥8.5B
/
Dec 2026
¥6.9B
=
1.2
Forward
¥8.5B
/
Dec 2027
¥7.4B
=
1.1
Forward
¥8.5B
/
Dec 2028
¥7.9B
=
1.1
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
KPC Pharmaceuticals Inc
SSE:600422
7.2B CNY 1.1 20.5
US
Eli Lilly and Co
NYSE:LLY
883B USD 13.5 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 5.7 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 4.7 27.6
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 4.2 14.8
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12
US
Pfizer Inc
NYSE:PFE
151.8B USD 2.4 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2.5 17.3
P/E Multiple
Earnings Growth PEG
CN
KPC Pharmaceuticals Inc
SSE:600422
Average P/E: 22.2
20.5
10%
2.1
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.6
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Lower than 77% of companies in China
Percentile
23nd
Based on 7 736 companies
23nd percentile
1.1
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

KPC Pharmaceuticals Inc
Glance View

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
10.17 CNY
Undervaluation 7%
Intrinsic Value
Price ¥9.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett